Medicines Source unknown
Dealstreet

Rajani, Vertices act on La Renon Healthcare investment in Enaltec Labs

The deal values Enaltec at a post-money valuation of ₹180-200 crore.

Bar & Bench

La Renon Healthcare, a pharmaceutical company has acquired 51% stake in Enaltec Labs. The deal values Enaltec at a post-money valuation of ₹180-200 crore.

Rajani Associates advised La Renon Healthcare and the team included:

  • Transation Team - Poorvi Sanjanwala (Partner), Nishtha Mehta (Senior Associate), Kashmira Bakliwal (Senior Associate) and Rutvik Rajagopal (Associate)

  • Diligence Team - Ankur Singhania (Partner), Kashmira Bakliwal, Rohan Gajaria and Rutvik Rajagopal.

Vertices Partners advised Enaltec Labs with a team led by Partners Amit Manubarwala and Vishal Mehta.

Managing Partner, Vinayak Burman provided strategic inputs.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Delhi High Court fines Congress leader's lawyer for coming unprepared in case against BJP leader

Media Law Column: Chilling speech in the age of social media influencers

Madras High Court flags trial courts' handling of vehicles seized in drug cases; says follow NDPS Act

We would be mad not to take advantage of the Indian market liberalisation: Stephen Moriarty KC

Win for PVR, BookMyShow as Bombay High Court allows convenience fees on online movie tickets

SCROLL FOR NEXT